The treatment of multiple sclerosis (MS) has undergone a remarkable transformation over the past 25 years. Beginning with the approval of IFNβ1b for relapsing remitting MS (RRMS) in 1993, the armamentarium of treatments for MS has grown; now 15 disease-modifying therapies are available and several others are approved for the treatment of specific symptoms. No other neuro logical disease has witnessed such remarkable progress, which is an outcome due in large part to a focus on understanding disease mechanisms and on the development of treatments that impact two clinical manifestations of the disease: relapses and disability accumulation. Although none of the available treatments can completely halt relapses and have small effects on the accumulation of disability, recent advances point to a potential future where clinicians can apply a precision medicine approach and achieve beneficial outcomes for people with relapsing forms of MS.
The approval of the first treatment for primary progressive MS (PPMS), ocrelizumab, in the United States, Europe and Australia, is a much-needed development for individuals with this form of the disease, and a source of hope for additional therapeutic advances 1,2 . Patient organizations, the scientific community and the pharma ceutical industry are increasingly focused on the challenges of progressive MS. Although crucial barriers exist, such as gaps in scientific knowledge, financial constraints and regulatory concerns, there is momentum and a collective will to overcome these challenges. Despite this optimism, an issue associated with the approval of ocrelizumab warrants careful consideration; a potential misalignment of stakeholder perspectives regarding progressive MS disease course descriptors, and their application in clinical trials and drug development.
Before 1996, a variety of clinical descriptions were used to characterize patient populations. This changed with the introduction of standardized definitions for the clinical course of MS: RRMS, PPMS, secondary progressive MS (SPMS) and progressive-relapsing MS (PRMS).
Although the 1996 standardized clinical course descriptors were useful as they enabled more effective communication between patients and clinicians and brought consistency in describing patient populations for clinical research studies, these descriptors were not specifically tied to the pathophysiological mechanisms of disease. A revision of MS descriptors in 2013 took the step of linking phenotypes to disease mechanisms by taking into account the presence of disease activity (relapse occurrence or lesion activity detected by CNS imaging) and/or progression of disability over a given time period. In addition, the 2013 descriptors distinguished RRMS from the progressive forms of the condition and, simultaneously emphasized the many similarities between PPMS and SPMS 3 . However, the authors of these revisions did not advocate combining PPMS and SPMS into one definition, given that there remain some important distinctions between the two forms of progressive MS.
Although the 2013 revision of MS disease course descriptors brought clarity to important gaps in communication and research, this clarity has not extended to the regulatory authorities. Instead, there appears to be a growing divergence in perspectives between the FDA and the European Medicines Agency (EMA) on this topic.
At present the EMA considers the subtypes of MS disease as distinct entities, whereas the FDA appears to view the disease subtypes as part of a continuum of one disease 4 . Although the FDA has not issued specific guidance on this topic, the agency's current perspectives are aptly illustrated in the publicly available summary of the ocrelizumab new drug application. In discussing the relapsing and primary progressive forms of MS, the agency wrote:
"… It is true that our thinking in the Division regarding the degree of relatedness has evolved … Previous advice was based on our perception of the understanding of the scientific community and our own understanding concerning the independence of the The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.
pathophysiological mechanisms underlying the forms of MS. We have evolved our thinking from our previous position, consistent with a contemporary understanding of MS. Our judgment is that these forms of MS are related, and the Division is prepared to accept PPMS and RMS [relapsing multiple sclerosis] populations as mutually supportive" (REF. 5 ). The apparent differences between the two agencies are reflected in their approval statements -with the FDA approving ocrelizumab for PPMS, whereas the EMA approval is for 'early' PPMS -a descriptor not previously used by the community 2 . The diverging viewpoints of the FDA and EMA could be perceived as a reflection of reasonable debate in the scientific community. However, given the global impact of these two regulatory authorities, a misalignment of their perspectives on a central issue such as MS disease courses could have substantial consequences on clinical development programmes in both the academic and industry sectors. Researchers and decision-makers could potentially experience uncertainty when deciding which regulatory view to follow in developing their programmes. Drug discovery is a challenging effort that requires considerable intellectual and financial commitment by stakeholders. Uncertainty, especially in regulatory matters, adds to this challenge and could introduce an additional disincentive for stakeholders to focus effort and investments in progressive MS.
A misalignment in perspectives between the regulators on the MS disease courses could also drive the academic and pharmaceutical communities towards a focus on treating a disease label -RRMS, PPMS, early PPMS and SPMS -instead of targeting the underlying disease mechanisms. Considerable progress has been made in distinguishing the inflammatory and neurodegenerative components of MS, although their relationship is still not well understood, and inflammatory and neurodegenerative processes may exist in parallel. Despite this, this knowledge is crucially important as we consider underlying mechanisms, with the aim of providing targets for effective treatment. Any move away from this position has the potential to create confusion and thereby delay the development of new treatments.
It is imperative that all stakeholders remain mindful of the fact that MS disease progression is the major determinant of disability, costs and quality of life and that understanding the mechanisms that underlie progression is the major obstacle to the development of effective treatments. Moreover, we cannot forget that these disease descriptors are affixed to individuals, thus, we should consider the implications of this debate on both the patient's treatment and their individual wellbeing.
Although the points discussed here have focused on the FDA and EMA, they are also of relevance to the MS patient, researcher, clinical and pharmaceutical communities. The key question is how will we, as a community, respond? It would be easy to criticize the regulators and demand solutions from them. The reality is that the views of the regulatory authorities are influenced by ongoing debate within the academic community, as well as their interactions with the pharmaceutical sector.
The onus falls on the MS scientific and patient communities to lead a global discussion on disease mechanisms that underpin the course of disease, to inform clinical research strategies, regulatory policies and perspectives. Such an effort must provide a clear consensus, based on what is already known, and determine the fundamental questions that need to be answered to provide the necessary clarity going forward. In addition, regulatory authorities should engage the scientific and patient communities in discussions to gauge opinions on disease mechanisms. Such discussions may be challenging to create, but they are the only way to bring a greater transparency to the processes by which the regulatory authorities develop their thinking and policy on such essential matters.
Failure to engage in these collective efforts will lead to a continuation of parallel perspectives in the academic, industry and regulatory sectors, which could create confusion and duplication of effort. Without focus and action we risk illogical situations, such as individuals with RRMS and PPMS having access to treatments, but people with SPMS being relegated to a therapeutic desert. Such a circumstance is unacceptable and requires concerted action by the global patient and research communities.
